AlzeCure Pharma
Alzecure: Reports Positive Phase I “MAD” results with ACD856 (Redeye)
2022-06-30 09:02
Redeye endorses the positive outcome from Alzecure’s phase I “MAD” study with drug candidate ACD856 and slightly raise our base case.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se